Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Sarepta Therapeutics Inc    SRPT

SAREPTA THERAPEUTICS INC

(SRPT)
  Report  
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsOfficial PublicationsSector newsAnalyst Recommendations
The feature you requested does not exist. However, we suggest the following feature:

Sarepta Therapeutics : Announces Inducement Grants Under Nasdaq Listing Rule 5635(4)

share with twitter share with LinkedIn share with facebook
share via e-mail
0
07/01/2019 | 08:51am EDT

CAMBRIDGE - Sarepta Therapeutics, Inc. (NASDAQ: SRPT), the leader in precision genetic medicine for rare diseases, granted equity awards on June 28, 2019, that were previously approved by the Compensation Committee of its Board of Directors under Sarepta's 2014 Employment Commencement Incentive Plan, as a material inducement to employment to twenty-eight individuals hired by Sarepta in June 2019.

The equity awards were approved in accordance with Nasdaq Listing Rule 5635(4).

The employees received, in the aggregate, options to purchase 27,295 shares of Sarepta's common stock, and in the aggregate, 13,640 restricted stock units ('RSUs'). The options have an exercise price of $151.95 per share, which is equal to the closing price of Sarepta's common stock on June 28, 2019 (the 'Grant Date'). One-fourth of the shares underlying each employee's option will vest on the one-year anniversary of the Grant Date and thereafter 1/48th of the shares underlying each employee's option will vest monthly, such that the shares underlying the option granted to each employee will be fully vested on the fourth anniversary of the Grant Date, in each case, subject to each such employee's continued employment with Sarepta on such vesting dates.

One-fourth of the RSUs will vest yearly on each anniversary of the Grant Date, such that the RSUs granted to each employee will be fully vested on the fourth anniversary of the Grant Date, in each case, subject to each such employee's continued employment with Sarepta on such vesting date.

About Sarepta Therapeutics

Sarepta is at the forefront of precision genetic medicine, having built an impressive and competitive position in Duchenne muscular dystrophy (DMD) and more recently in gene therapies for 6 Limb-girdle muscular dystrophy diseases (LGMD), Charcot-Marie-Tooth (CMT), MPS IIIA, Pompe and other CNS-related disorders, totaling over 20 therapies in various stages of development. The Company's programs and research focus span several therapeutic modalities, including RNA, gene therapy and gene editing. Sarepta is fueled by an audacious but important mission: to profoundly improve and extend the lives of patients with rare genetic-based diseases.

Internet Posting of Information

We routinely post information that may be important to investors in the 'For Investors' section of our website at www.sarepta.com. We encourage investors and potential investors to consult our website regularly for important information about us.

Contact:

Ian Estepan

Tel: 617-274-4052

Email: iestepan@sarepta.com

(C) 2019 Electronic News Publishing, source ENP Newswire

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on SAREPTA THERAPEUTICS INC
07/01SAREPTA THERAPEUTICS : Announces Inducement Grants Under Nasdaq Listing Rule 563..
AQ
06/28Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 56..
GL
06/28Sarepta surges after Pfizer gene therapy data raises safety concerns
RE
06/07SAREPTA THERAPEUTICS, INC. : Submission of Matters to a Vote of Security Holders..
AQ
06/04Sarepta Therapeutics to Present at the Goldman Sachs 40th Annual Global Healt..
GL
05/31Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 56..
GL
05/23SAREPTA THERAPEUTICS : Statement on ICER Draft Evidence Report for Treatments fo..
PU
05/23CATALENT : new prize, Paragon, adding capacity to make Sarepta gene therapies
AQ
05/09SAREPTA THERAPEUTICS : Announces Agreement with Nationwide Children's Hospital f..
AQ
05/09SAREPTA THERAPEUTICS : Announces Agreement with Nationwide Childrens Hospital fo..
AQ
More news
Financials (USD)
Sales 2019 390 M
EBIT 2019 -346 M
Net income 2019 -347 M
Finance 2019 686 M
Yield 2019 -
P/E ratio 2019 -33,2x
P/E ratio 2020 -48,3x
EV / Sales2019 27,5x
EV / Sales2020 17,8x
Capitalization 11 420 M
Chart SAREPTA THERAPEUTICS INC
Duration : Period :
Sarepta Therapeutics Inc Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends SAREPTA THERAPEUTICS INC
Short TermMid-TermLong Term
TrendsBullishBullishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 23
Average target price 210,00  $
Last Close Price 154,00  $
Spread / Highest target 78,6%
Spread / Average Target 36,4%
Spread / Lowest Target 11,7%
EPS Revisions
Managers
NameTitle
Douglas S. Ingram President, Chief Executive Officer & Director
M. Kathleen Behrens Chairman
Sandesh Mahatme Executive VP, Chief Financial & Business Officer
Guriqbal S. Basi Chief Scientific Officer
Gilmore O’Neill Chief Medical Officer & Senior Vice President
Sector and Competitors
1st jan.Capitalization (M$)
SAREPTA THERAPEUTICS INC41.12%0
GILEAD SCIENCES6.99%84 164
VERTEX PHARMACEUTICALS6.90%45 080
REGENERON PHARMACEUTICALS-19.83%31 857
GENMAB14.24%11 148
ARRAY BIOPHARMA INC224.63%10 445